Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.61 |
| ▸ | NOS1 | P29475 | 2/20 | 0.61 |
| ▸ | NOS2 | P35228 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565143 | 0.90 | NOS3 (0.61) | NOS3NOS1NOS2CYP3A4LPAR3 | |
| SCHEMBL29177519 | 0.78 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL15389152 | 0.78 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL26559 | 0.78 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL6562227 | 0.78 | — | — | |
| Iodide SCHEMBL5047411 | 0.76 | — | — | |
| Bromide SCHEMBL4732426 | 0.76 | — | — | |
| Methane SCHEMBL11359992 | 0.76 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL945567 | 0.76 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL150664 | 0.76 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318238-A1 | METHODS FOR REDUCING SEQUELAE OF INTRA-DIALYTIC HYPOTENSION | FARFARA ROY (CY) | 2018-11-08 | — | — | US | claimed |
| CN-101917848-A | S-alkylisothiouronium derivatives for the treatment of uterine hypercontractility disorders | BARKAN FARMA S R L | 2010-12-15 | — | — | CN | claimed |
| US-20100311691-A1 | COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING UPPER RESPIRATORY CONGESTION | BARKAN REFAEL | 2010-12-09 | — | — | US | claimed |
| US-20100305210-A1 | S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING ABNORMAL UTERINE BLEEDING DISORDERS | BARKAN-FARMA S.R.L. (MD) | 2010-12-02 | — | — | US | claimed |
| US-20100285127-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES | MEDITOR PHARMACEUTICALS LTD. (IL) | 2010-11-11 | — | — | US | claimed |
| EP-2219447-A2 | S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING UTERINE HYPERCONTRACTILITY DISORDERS | Barkan-Farma S.r.l. (MD) | 2010-08-25 | — | — | EP | claimed |
| EP-2219446-A2 | COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING UPPER RESPIRATORY CONGESTION | Barkan-Farma S.r.l. (MD) | 2010-08-25 | — | — | EP | claimed |
| EP-2167050-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES | Meditor Pharmaceuticals Ltd. (IL) | 2010-03-31 | — | — | EP | claimed |
| US-20090186854-A1 | S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | MEDITOR PHARMACEUTICALS LTD. (IL) | 2009-07-23 | — | — | US | claimed |
| WO-2009060450-A2 | COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING UPPER RESPIRATORY CONGESTION | BARKAN-FARMA S.R.L. (MD) | 2009-05-14 | — | — | WO | claimed |
| WO-2007029255-A1 | PREVENTION OF HYPOTENSION AND STABILIZATION OF BLOOD PRESSURE IN HEMODIALYSIS PATIENTS | MEDITOR PHARMACEUTICALS LTD. (IL) | 2007-03-15 | — | — | WO | claimed |
| US-7148208-B2 | Pharmaceutical compositions for headache, migraine, nausea and emesis | MEDITOR PHARMACEUTICALS LTD. (IL) | 2006-12-12 | — | — | US | claimed |
| EP-1315505-A4 | PHARMACEUTICAL COMPOSITIONS FOR HEADACHE, MIGRAINE, NAUSEA AND EMESIS | MEDITOR PHARMACEUTICALS LTD (IL) | 2006-02-22 | — | — | EP | claimed |
| US-20040006044-A1 | Pharmaceutical compositions for headache, migraine, nausea and emesis | MEDITOR PHARMACEUTICALS LTD. (IL) | 2004-01-08 | — | — | US | claimed |
| EP-1315505-A2 | PHARMACEUTICAL COMPOSITIONS FOR HEADACHE, MIGRAINE, NAUSEA AND EMESIS | Meditor Pharmaceuticals Ltd. (IL) | 2003-06-04 | — | — | EP | claimed |
| EP-0928191-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING S-ALKYLISOTHIOURONIUM DERIVATIVES | MEDITOR PHARMACEUTICALS LTD (IL) | 2002-08-28 | — | — | EP | claimed |
| WO-2002019961-A2 | PHARMACEUTICAL COMPOSITIONS FOR HEADACHE, MIGRAINE, NAUSEA AND EMESIS | MEDITOR PHARMACEUTICALS LTD. (IL) | 2002-03-14 | — | — | WO | claimed |
| US-6160008-A | Pharmaceutical compositions comprising S-alkylisothiouronium derivatives | MEDITOR PHARMACEUTICALS LTD. (IL) | 2000-12-12 | — | — | US | claimed |
| EP-0928191-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING S-ALKYLISOTHIOURONIUM DERIVATIVES | Meditor Pharmaceuticals Ltd. (IL) | 1999-07-14 | — | — | EP | claimed |
| WO-1998013036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING S-ALKYLISOTHIOURONIUM DERIVATIVES | MEDITOR PHARMACEUTICALS LTD. (IL) | 1998-04-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318238-A1 | METHODS FOR REDUCING SEQUELAE OF INTRA-DIALYTIC HYPOTENSION | REN, SLC6A5, SLC6A12 | NOS3 1108/4885NOS1 1882/4885NOS2 1042/4885 |
| US-20100311691-A1 | COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING UPPER RESPIRATORY CONGESTION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TAS2R7, ADRB1 | NOS3 1091/4885NOS1 1481/4885NOS2 1507/4885 |
| US-20100285127-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES | TAS2R5, TAS2R40, TAS2R30 | NOS3 2946/4885NOS1 3835/4885NOS2 3695/4885 |
| US-20090186854-A1 | S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPMT, TST, TNF | NOS3 423/4885NOS1 466/4885NOS2 238/4885 |
| US-20100305210-A1 | S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING ABNORMAL UTERINE BLEEDING DISORDERS | ITPR3, KCNN3, KCNN2 | NOS3 1731/4885NOS1 3072/4885NOS2 2431/4885 |
| US-20040006044-A1 | Pharmaceutical compositions for headache, migraine, nausea and emesis | MGMT, TRPA1, HNMT | NOS3 1855/4885NOS1 2729/4885NOS2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.